Sarepta CEO To Jump Ship After 'Tumultuous' Year

Earnings Snapshot - Sarepta Therapeutics reported an adjusted loss of $3.58 per share, missing Wall Street's estimate of a loss of $1.31 [1] - Sales reached $442.93 million, exceeding the consensus estimate of $391.92 million [1] - Sales fell 33% year over year, primarily due to a $273.8 million decrease in net product revenue from Elevidys, following the suspension of shipments to non-ambulatory patients in the U.S. [1] Management Transition - Douglas Ingram announced his plan to retire as CEO by the end of 2026 or upon the appointment of his successor, with the company beginning a search for a replacement [2] Analyst View - Analysts express caution regarding the company's future, particularly after the failure of the ESSENCE trial, which raises concerns about the marketing authorization of Vyondys 53 and Amondys 45 [3] Stock Performance and Technical Analysis - The stock is currently trading 3.5% below its 20-day simple moving average (SMA) and 9.8% below its 100-day SMA, indicating a bearish trend [5] - Over the past 12 months, shares have significantly decreased and are closer to their 52-week lows [5] - The RSI is at 50.00, indicating neutral territory, while the MACD at -0.10 suggests bearish pressure on the stock [6] Price Action - Sarepta Therapeutics shares were down 3.53% at $18.30 during premarket trading [7] - Key resistance level is at $20.00, while key support is at $15.00 [7]